{"schema_version":"secwatch.filing_event.v1","accession":"0001792044-23-000021","form_type":"8-K","ticker":"VTRS","cik":"0001792044","company_name":"Viatris Inc","filed_at":"2023-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.263218+00:00","generated_at":"2026-06-12T04:37:34.119100+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Viatris reports strong Q2 2023: revenue $3.92B, net income $264M, reaffirms guidance","bullets":["Total revenues $3.92B, U.S. GAAP net earnings $264M, adjusted EBITDA $1.31B, free cash flow $447M.","Reaffirms full-year 2023 total revenues, adjusted EBITDA and free cash flow expected at midpoint of guidance ranges.","Board declared $0.12/share dividend, payable Sept 15, record Aug 24 (unchanged from prior).","Paid down $727M debt YTD; on track to announce planned divestitures in 2023, with at least one significant in Q3.","Launched Breyna (generic Symbicort) in July; new product revenue target on track."],"urls":{"canonical":"https://secwatch.observer/filing/0001792044-23-000021","json":"https://secwatch.observer/filing/0001792044-23-000021.json","markdown":"https://secwatch.observer/filing/0001792044-23-000021.md","text":"https://secwatch.observer/filing/0001792044-23-000021.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1792044/000179204423000021/0001792044-23-000021-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1792044/000179204423000021/vtrs-20230807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T04:37:34.119100+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b297d87fe155a80bc4f6db0545bf17e47634bee6","claim":"Viatris Inc reported second quarter 2023 results: revenue $3.92 Billion, net income $264 Million. Guidance reaffirmed.","evidence_excerpt":"Viatris Reports Strong Financial and Operational Results for Second Quarter 2023 and Reaffirms Full-Year 2023 Guidance Ranges[1] • Reports Total Revenues of $3.92 Billion; U.S. GAAP Net Earnings of $264 Million; Adjusted EBITDA of $1.31 Billion; U.S. GAAP Net Cash Provided by Operating Activities of $515 Million; and Free Cash Flow of $447 Million for the Quarter","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1792044/000179204423000021/0001792044-23-000021-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter 2023"},{"label":"Revenue","value":"$3.92 Billion"},{"label":"Net income","value":"$264 Million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}